Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke
Neurodegeneration is a hallmark of most of the central nervous system (CNS) disorders including stroke. Recently inflammation has been implicated in pathogenesis of neurodegeneration and neurodegenerative diseases. The aim of this study was analysis of expression of several inflammatory markers and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/727189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565231958622208 |
|---|---|
| author | Pawel Wolinski Andrzej Glabinski |
| author_facet | Pawel Wolinski Andrzej Glabinski |
| author_sort | Pawel Wolinski |
| collection | DOAJ |
| description | Neurodegeneration is a hallmark of most of the central nervous system (CNS) disorders including stroke. Recently inflammation has been implicated in pathogenesis of neurodegeneration and neurodegenerative diseases. The aim of this study was analysis of expression of several inflammatory markers and its correlation with development of neurodegeneration during the early stage of experimental stroke. Ischemic stroke model was induced by stereotaxic intracerebral injection of vasoconstricting agent endothelin-1 (ET-1). It was observed that neurodegeneration appears very early in that model and correlates well with migration of inflammatory lymphocytes and macrophages to the brain. Although the expression of several studied chemotactic cytokines (chemokines) was significantly increased at the early phase of ET-1 induced stroke model, no clear correlation of this expression with neurodegeneration was observed. These data may indicate that chemokines do not induce neurodegeneration directly. Upregulated in the ischemic brain chemokines may be a potential target for future therapies reducing inflammatory cell migration to the brain in early stroke. Inhibition of inflammatory cell accumulation in the brain at the early stage of stroke may lead to amelioration of ischemic neurodegeneration. |
| format | Article |
| id | doaj-art-50f2c11964734f24a75660339499f695 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-50f2c11964734f24a75660339499f6952025-02-03T01:08:59ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/727189727189Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic StrokePawel Wolinski0Andrzej Glabinski1Department of Propedeutics of Neurology, Medical University of Lodz, ul. Pabianicka 62, Lodz, PolandDepartment of Propedeutics of Neurology, Medical University of Lodz, ul. Pabianicka 62, Lodz, PolandNeurodegeneration is a hallmark of most of the central nervous system (CNS) disorders including stroke. Recently inflammation has been implicated in pathogenesis of neurodegeneration and neurodegenerative diseases. The aim of this study was analysis of expression of several inflammatory markers and its correlation with development of neurodegeneration during the early stage of experimental stroke. Ischemic stroke model was induced by stereotaxic intracerebral injection of vasoconstricting agent endothelin-1 (ET-1). It was observed that neurodegeneration appears very early in that model and correlates well with migration of inflammatory lymphocytes and macrophages to the brain. Although the expression of several studied chemotactic cytokines (chemokines) was significantly increased at the early phase of ET-1 induced stroke model, no clear correlation of this expression with neurodegeneration was observed. These data may indicate that chemokines do not induce neurodegeneration directly. Upregulated in the ischemic brain chemokines may be a potential target for future therapies reducing inflammatory cell migration to the brain in early stroke. Inhibition of inflammatory cell accumulation in the brain at the early stage of stroke may lead to amelioration of ischemic neurodegeneration.http://dx.doi.org/10.1155/2013/727189 |
| spellingShingle | Pawel Wolinski Andrzej Glabinski Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke Mediators of Inflammation |
| title | Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke |
| title_full | Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke |
| title_fullStr | Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke |
| title_full_unstemmed | Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke |
| title_short | Chemokines and Neurodegeneration in the Early Stage of Experimental Ischemic Stroke |
| title_sort | chemokines and neurodegeneration in the early stage of experimental ischemic stroke |
| url | http://dx.doi.org/10.1155/2013/727189 |
| work_keys_str_mv | AT pawelwolinski chemokinesandneurodegenerationintheearlystageofexperimentalischemicstroke AT andrzejglabinski chemokinesandneurodegenerationintheearlystageofexperimentalischemicstroke |